In the process of analyzing the effects of lipoproteins on functions of lymphoid cells, it was observed that physiological concentrations of isolated human plasma lipoproteins possess varying capacities to rapidly enhance the expression of procoagulant activity of human peripheral blood mononuclear cells in vitro. In a strict dose-dependent fashion, very low density lipoprotein, intermediate density lipoprotein, and high density lipoprotein enhanced both the surface expression by viable cells and the total cellular content of procoagulant activity during a 6-h incubation. Very low density lipoprotein induced a maximal 6.7-fold increase in the expression of a thromboplastin activity, which was consistent with tissue factor, in that it was dependent on Factors VII, X, and II. Both intermediate density lipoprotein and high density lipoprotein induced approximately a 12-fold increase of a different procoagulant activity which appears to be a direct prothrombin activator. This prothrombinase was calcium dependent and was inhibited by 2.5 mM diisopropylfluorophosphate, but was not neutralized by anti-Factor X antibodies or by inhibitors of Factor Xa. In contrast to the other lipoprotein density classes, low density lipoprotein did not stimulate procoagulant activity, but instead actively suppressed the generation of the two procoagulant activities induced by the stimulatory lipoproteins. Suppression by low density lipoprotein was clearly evident at molar ratios of low density lipoprotein to stimulatory lipoproteins of 1:3 or less. Reconstitution […] Find the latest version: 
In the process of analyzing the effects of lipoproteins on functions of lymphoid cells, it was observed that physiological concentrations of isolated human plasma lipoproteins possess varying capacities to rapidly enhance the expression of procoagulant activity of human peripheral blood mononuclear cells in vitro. In a strict dose-dependent fashion, very low density lipoprotein, intermediate density lipoprotein, and high density lipoprotein enhanced both the surface expression by viable cells and the total cellular content of procoagulant activity during a 6-h incubation. Very low density lipoprotein induced a maximal 6.7-fold increase in the expression of a thromboplastin activity, which was consistent with tissue factor, in that it was dependent on Factors VII, X, and II. Both intermediate density lipoprotein and high density lipoprotein induced approximately a 12-fold increase of a different procoagulant activity which appears to be a direct prothrombin activator. This prothrombinase was calcium dependent and was inhibited by 2.5 mM diisopropylfluorophosphate, but was not neutralized by anti-Factor X antibodies or by inhibitors of Factor Xa. In contrast to the other lipoprotein density classes, low density lipoprotein did not stimulate procoagulant activity, but instead actively suppressed the generation of the two procoagulant activities induced by the stimulatory lipoproteins. Suppression by low density lipoprotein was clearly evident at molar ratios of low density lipoprotein to stimulatory lipoproteins of 1:3 or less. Reconstitution […] INTRODUCTION Lymphoid cells, as exemplified by peripheral blood mononuclear cells (PBM),1 can be stimulated to generate procoagulant activity (PCA) by a variety of stimuli including lipopolysaccharide (LPS) (1-3), antigenantibody complexes (4), mitogenic lectins (5), and proteolytic products of complement (C) 5 (6) . The LPSinduced procoagulant activity of human mononuclear cells has been characterized as a tissue thromboplastin that binds plasma Factor VII and initiates the sequence of enzymatic cleavages of the extrinsic pathway of blood coagulation (7) . These events culminate in the conversion of prothrombin to the serine protease thrombin, which induces the formation of an insoluble fibrin gel from soluble fibrinogen and also induces platelet aggregation.
Lipids participate significantly in the assembly of proteins of the coagulation sequence as exemplified by their requisite role as a cofactor in the proteolytic generation ofactivated Factor X, as well as the assembly of Xa, Va, and prothrombin to generate thrombin (8) .
In studies of the effects of plasma lipoproteins on intrinsic blood coagulation, lipoproteins have been observed to accelerate coagulation in a number of plasma clotting assays (9, 10) . Plasma lipoproteins are also potent immunoregulatory molecules and are capable of affecting a variety of lymphocyte functions both in vitro and in vivo (11) (12) (13) (14) . The effects, however, of plasma lipoproteins on the expression of PCA by PBM have not been recognized.
In the process of analyzing the regulation of lymphocyte function by plasma lipoproteins, it was observed that certain classes of isolated lipoproteins could induce the generation of PCA by PBM in culture, whereas others could not. We here report these in vitro observations and speculate on the possible in vivo implications of this newly described phenomenon. An accompanying paper describes the cellular requirements for plasma lipoprotein induction and suppression of this cellular PCA expression. Lipoproteins were delipidated at 220C by chloroform extraction (19) Cell isolation and culture conditions. Human PBM were isolated from the blood of fasting healthy donors by centrifugation over Ficoll-Hypaque (20) at 1,400 g at 22°C for 12 min, washed three times with RPMI-1640 (Grand Island Biological Co., Grand Island, N. Y.), and resuspended at 1 x 106 cells/ml in complete medium (10% fetal calf serum in PRMI-1640, 100 U/ml penicillin 50 ,ug/ml streptomycin). Viability was >98% by trypan blue exclusion. The PBM contained an average of 85% lymphocytes, 12% monocytes and 3% or less contaminating polymorphonuclear leukocytes as assessed by cytology, vital uptake of neutral red and nonspecific esterase stains (21) .
METHODS
PBM at 1 x 106/ml were incubated in complete medium at 370C in 6% CO2 in 12 x 75-mm polypropylene tubes (Falcon Labware, Div. Beckton Dickinson & Co., Oxnard, Calif). 6 h after the addition of test material, the cells were washed twice with RPMI-1640, unless otherwise indicated, and cell viability assessed by trypan blue exclusion before assay of cellular PCA. Bacterial LPS (Escherichia coli 0111 B4, butanol extracted) was kindly provided by Dr. David Morrison, Emory University, Atlanta, Ga. It was used as a positive control at a final concentration of 10 ,uglml.
Procoagulant activity. PCA was quantitated in a one-stage clotting assay (3). The PBM were assayed for either viable or total content. For assay of viable cells the washed cell pellet was resuspended in 1.0 ml of RPMI-1640. For assay of total cellular content, the washed cell pellet was frozen at -70°a nd thawed at 370C three times and then sonicated in 0.5 ml RPMI-1640 under previously determined optimal conditions with a microtip probe of a model W-140 sonicator (Heat Systems-Ultrasonics, Inc., Plainview, N. Y.) at a setting of 3 using two 10-s bursts, each with ice cooling. A second 0.5 ml of RPMI-1640 was added to bring the final volume to 1.0 ml. In brief, the clotting assay (3) consisted of 0.1 ml cell sample (either viable or homogenized cells) and 0.1 ml of citrated normal human platelet-poor plasma, or factor-deficient plasma (George King Biomedical Inc., Overland Park, Kan.) The reaction was initiated by the addition of 0.1 ml of 25 mM CaCl2 and the time (in seconds) for the initial appearance of an insoluble fibrin clot with manual rocking at 37°C was recorded. A rabbit brain thromboplastin standard at 36 mg dry mass/ml (Dade Div., American Hospital Supply Corp., Miami, Fla.) was assigned a value of 100,000 mU. Clotting times for 0 and 10,000 mU of thromboplastin were 196 and 24 s, respectively. Data are expressed as the mean and standard deviation of replicate assays. Precision of the assay varied from 6.1 to 9.7% (coefficient of variation). RPMI-1640 with or without 10% fetal calf serum, lipoprotein buffer, and 10 i.g/ml LPS were without PCA, based on the clotting time of recalcified platelet-poor plasma. In addition, coagulation of recalcified normal platelet-poor plasma was not accelerated in the presence of 1.0, 1.25, 3.0, and 3.1 mg protein of intact VLDL, IDL, LDL, and HDL, respectively. Contamination of the lipoproteins with plasma coagulation Factors VII, IX, and X was assayed by standard prothrombin time and by activated partial thrombplastin time (22) with the aid of hereditary factor-deficient plasmas. The limits of detection were determined from standard curves established by supplementing the deficient plasmas with 0.1-20% normal human plateletpoor plasma. The limits of detection were 0.2% for Factor VII, 0.1% for Factor IX and 0.4% for Factor X. There was no correction of the assays in the presence of VLDL, IDL, or HDL at the above concentrations. On an assumption ofnormal plasma concentrations of -10, 3, and 10 ,ug/ml for Factors VII, IX, and X, respectively (22) ; the lipoproteins were free of functional Factor VII, IX, and X activity at levels of 0.02 ug Lipoprotein Induction of Cellular Procoagulant ActivityFactor VII, 0.003 ,ug Factor IX, and 0.04 isg Factor X/mg of lipoprotein protein.
Assay of direct prothrombin cleavage. Factor X and prothrombin were isolated from Cohn Fraction III as previously described (23) and were separated from each other by chromatography on heparin-agarose equilibrated in 0.02 M 2(N-morpholino) ethane sulfonic acid/Tris, pH 5.9, containing 0.1 M NaCl, 2 mM benzamidine, and 0.02% NaN3. Immediately before chromatography, the protein solution was adjusted to 2.5 mM CaCl2. The column was developed with a linear salt gradient from 0.1-1.0 M NaCl in the equilibration buffer containing 2.5 mM CaCl2. The nonbinding fraction contained prothrombin which was then rechromatographed over a second heparin-agarose column in 0.02 M 2(Nmorpholino) ethane sulfonic acid/Tris, pH 6.0, containing 0.02% NaN3, 2 mM benzamidine, and 2 mM CaCl2. The protein was eluted with a linear 0-0.3 M NaCl gradient in this buffer. Human Laemmli (25) . Following electrophoresis, the gels were fixed, dried, and analyzed by autoradiography for 125I-prothrombin and its cleavage products.
To assess the susceptibility of IDL-or HDL-induced PCA to various protease inhibitors, 50-,ul aliquots of cell homogenate from HDL-or IDL-stimulated PBM were incubated with each of the following protease inhibitors: antithrombin III (10 ,ug/ml) in the presence or absence of I U/ml heparin, trasylol (10 U/ml), soybean trypsin inhibitor (10 ,ug/ml), benzamidine (1 mM), phenylmethylsulfonyl fluoride (1 mM), and diisopropylfluorophosphate (2.5 and 10 mM). After 5 min incubation with the inhibitor at 22°C, 10 IAl of 0.1 mM 1251-prothrombin and 10 ,ul of 25 mM' CaCl2 were added, and the reactions were incubated an additional 30 min at 37°C. 123I.Prothrombin cleavage was assessed by SDS-polyacrylamide gel electrophoresis (PAGE) and autoradiography. Percent inhibition of 125I-prothrombin cleavage was determined from the autoradiographs by soft laser scanning densitometry (Zeineh soft laser, Biomed Instruments, Inc., Chicago, Ill.). Human Factor Xa (0.5 jAg/ml), in the presence ofhomogenates of unstimulated cells, was treated identically for comparison.
Antibody neutralization of PCA was examined using rabbit antisera to human Factor X (23). The IgG fraction of normal rabbit serum (1 mg/ml), or the IgG fraction of rabbit antiFactor X immune serum (1 mg/ml with a 1:64 titer for half neutralization of normal human plasma) was added to Human Factor Xa (0.5 ,ug/ml in the presence of homogenates of 106 unstimulated PBM), or to homogenates of IDL-or HDLexposed PBM (106 cells/ml). Aliquots were removed immediately, and after 6 h of incubation at 22°C, combined with 1251-prothrombin and CaCl2 at 37°C for 45 min, and subjected to SDS-PAGE to assess 1251-prothrombin cleavage at each time point. Percent prothrombin cleavage was quantitated from autoradiographs by soft laser densitometry.
Viable cells and cell homogenates of basal and stimulated PBM were also tested for functional direct prothrombin activation. Fibrinogen (50 ,ul of 4 mg/ml), prothrombin (50 ,ll of 100 ,g/ml), and the intact cells or cell homogenates (100 ,ul) were combined in a glass tube. Calcium chloride (100 ,ul of 25 mM) was added to initiate the reaction at 37°C, and the time (in seconds) required for the appearance of insoluble fibrin with manual rocking was recorded.
RESULTS
Lipoprotein stimulation of procoagulant activity. Isolated PBM expressed low (basal) levels of PCA which was demonstrated by assay of either viable cells or disrupted cell homogenates (Table I) . PBM cultured for 6 h at 370C in the presence of 10 ,ug/ml LPS, a known inducer of cellular PCA (2) , exhibited at 7.4-and 15.3-fold increase in the viable expression and total cellular content of PCA, respectively (Table I ). The PCA increase induced by LPS was identified using clotting factor-deficient plasmas as a Factor VII-, X-, and II-dependent activity (Table II) which was consistent with the generation of tissue factor as previously described (2, 7).
Individual density classes of human plasma lipoproteins isolated by standard differential ultracentrifugation demonstrated varying capacities to induce PCA when they were added to the PBM cultures. Both the viable expression and the total cellular content of PCA increased in response to incubation for 6 h at 37°C with either VLDL, IDL, or HDL, whereas no significant increase was noted with LDL (Table I) in the basal (unstimulated) level of PCA was also observed with time, whereas again LDL exhibited no stimulatory activity. Dose titrations performed on each of the plasma lipoproteins demonstrated a 10-fold increase in total PCA by incubation with IDL and HDL to 50 and 500 ,ug protein/ml, respectively, whereas VLDL induced a maximal 6-fold stimulation at 50 ,ug/ml (Fig. 2) . These protein concentrations of stimulatory lipoproteins were all within the physiological range of normal plasma lipoproteins in adult human plasma (26) , and were reproducible within experimental error for six lipoprotein isolations during the course of this study. The observed dose-dependent amplification of PCA was not dependent upon the presence of fetal calf serum in the PBM cell cultures, since similar experiments performed in the absence of serum gave reproducibly comparable results (data not shown).
Suppression of procoagulant activities by LDL. In contrast to the stimulatory lipoproteins, LDL at concentrations as high as 1 mg/ml, a supraphysiological concentration (26) , induced no increase in PCA over basal levels, and appeared to be somewhat inhibitory at high concentrations ( Figs. 1 and 2 ). To assess this further, the stimulatory lipoproteins were added to PBM cultures containing varying amounts of LDL. The concentrations of stimulatory lipoproteins used were chosen from the dose-response curves (Fig. 2) to give -95% of maximum PCA induction, i.e., 50, 50, and 500 Fg protein/ml for VLDL, IDL, and HDL, respectively. After a 6-h incubation at 37°C, >95% of the cellular PCA induced by VLDL, IDL, or HDL was prevented by 50, 50, and 200 ,g LDL/ml, respectively. This was not due to direct cellular toxicity since in all cases the cell viability and recovery was >94%. No inhibition of PCA generation was observed when 5 10 50 100 500 1000
Lipoproteins (Ag protein/ml cell suspension) 5000 FIGuRE 2 The induction of procoagulant activity in PBM by incubation with plasma lipoproteins in vitro is dose dependent. The PBM (1 x 106 in 1 ml) were cultured for 6 h at 37°C in the presence of the lipoproteins before assay of total PCA content.
Lipoprotein Induction of Cellular Procoagulant Activity (Table III) . Thus, the net effect of the simultaneous addition of LDL to either VLDL-, IDL-, and/ or HDL-stimulated PBM cultures was the expression of only basal levels of PCA. Characterization of the procoagulant activities. The type of PCA generated in PBM by the stimulatory lipoproteins was identified by a one-stage clotting assay using plasmas deficient for single human coagulation factors (Table II) . The activity generated by incubation with VLDL was Factor VII, X, and II dependent, which is consistent with activation by tissue factor via the extrinsic coagulation pathway. Similar results were found for LPS-induced PCA. In contrast, most of the activity induced by incubation of PBM with either IDL or HDL occurred via a pathway that appeared independent of Factor VII of the extrinsic coagulation pathway, Factor IX and VIII of the intrinsic pathway, and Factor X of the common pathway (Table II) . This IDL-or HDL-induced activity was only Factor IIdependent, and suggested that prothrombin was converted to thrombin by a direct prothrombin activator.
This was confirmed by assaying prothrombin cleavage directly. Cell homogenates prepared from PBM incubated with the stimulatory lipoproteins or LPS were added to 1251-prothrombin in the presence of 25 mM CaCl2 for 30 min at 37°C. Prothrombin cleavage was assessed by SDS-PAGE of the reaction mixtures followed by autoradiographic display (Fig. 3) .
Smaller molecular weight cleavage products of 125I1 prothrombin were obtained from PBM cell homogenates stimulated with HDL ( Fig. 3) and IDL (not shown), whereas no direct prothrombin cleavage was observed with either LPS-or VLDL-stimulated PBM cell homogenates. The HDL-or IDL-induced prothrombin cleavage products, although qualitatively similar to those generated by isolated human Factor Xa, did not appear to be precisely identical (Fig. 3) . Furthermore, both viable cells and cell homogenates of IDL-or HDL-stimulated PBM, when added to isolated prothrombin and fibrogen in the presence of CaCl2, initiated the formation of a fibrin clot (Table IV) . Although expressed by viable cells, this PCA was not present in the 100,000-g supernatant medium of stimulated cells, but was found in the pellet of cellular material, which suggests that it is cell associated. Thus, these IDL-and HDL-stimulated PBM contained an enzyme which cleaved prothrombin, and the products ofthis cleavage were (Table IV) . Similarly, neither the cell homogenates nor Factor Xa clotted fibrinogen in the absence of prothrombin (data not shown). The identity of the cellular PCA induced by IDL and HDL was further examined with respect to neutralization by anti-Factor X antibody. The IgG fraction of a rabbit antiserum to human Factor X markedly attenuated the cleavage of 125I-prothrombin by Factor Xa, and therefore contained neutralizing antibody for Factor Xa activity. This same antibody, however, did not attenuate the cleavage of 125I-prothrombin by the PCA present in the cell homogenates of IDL-or HDLstimulated PBM (Table V) . Similarly, when functional direct prothrombin activation was tested by observing clot formation in the presence of CaC12, prothrombin, and fibrinogen, the anti-Factor X IgG neutralized Factor Xa activity (assayed in the presence of unstimulated cell homogenates), but did not neutralize the IDL-or HDL-induced cellular PCA (data not shown).
We next examined the ability of protease inhibitors to prevent 125I-prothrombin cleavage by purified Factor Xa, and by IDL-and HDL-induced cellular PCA (Table  VI) . Whereas >80% inhibition of Factor Xa activity was observed with antithrombin III in the presence of heparin, soybean trypsin inhibitor, and phenyl-methylsulfonyl fluoride, none of these inhibited the cellular prothrombin cleaving activity. In contrast, Factor Xa was much less sensitive to diisopropylfluorophosphate than was the cellular prothrombin cleaving activity (Table VI) . These combined data suggest that the IDLand HDL-induced prothrombin cleaving activity may not be Factor Xa, but rather a serine protease. "Cell homogenates of 1 x 106f PBM which had been incubated for 10 h with 50 ,ug/ml IDL or 500 ,ug/ml HDL. DISCUSSION This study provides evidence for a previously unrecognized reciprocal regulatory network whereby differing plasma lipoproteins can, through interaction with peripheral blood mononuclear cells, initiate or suppress cellular procoagulant activities. This study further indicates that certain plasma lipoproteins are potent stimulants of PBM-derived PCA. The normal concentration ranges of these lipoproteins in plasma are 70-180, 80-120, 725-840, and 1,300-1,600 ,ug lipoprotein protein/ml for VLDL, IDL, LDL, and HDL, respectively (26) . Among these lipoprotein density classes, IDL appeared to be the most potent procoagulant stimulant on a protein basis with maximal activity at 50 ,ug protein/ml. HDL was a similarily potent stimulant at a 10-fold higher protein concentration, whereas VLDL induced lesser amounts of PCA at protein concentrations identical to those of IDL. Whether these biological activities reside in the major lipoproteins of these classes or in minor lipoprotein subclasses is a topic for study. Procoagulant activity was expressed by viable cells, indicative of either cellsurface expression or secretion but >85% ofthe activity was observed only after the cells were disrupted, which suggests the existence of a predominant functionally active intracellular pool.
Both the magnitude and the substrate requirements of the PCA induced by VLDL differed from that induced by either IDL or HDL. VLDL-induced PCA, like LPS-induced PCA, appeared to be a classical Lipoprotein Induction of Cellular Procoagulant Activity VII-or Factor X-deficient plasmas, and (b) its capacity to generate functional thrombinlike products proteolytically from prothrombin. Such maneuvers define the expression by these cells of two forms of inducible PCA, but do not at this point establish the molecular characteristics of the inducible prothrombinase. A series of observations suggests that it is not free Factor Xa. Free Factor Xa was not detectable by radioimmunoassay (23) in quantities <0.2% of that required for equivalent prothrombin cleavage. In addition, the cellular prothrombinase was not neutralized by antiFactor Xa antibodies, antithrombin III in the presence of heparin, phenylmethyl-sulfonyl fluoride, or soybean trypsin inhibitor, a particularly potent inhibitor of Factor Xa. It was, however, more sensitive than Factor Xa to diisopropylfluorophosphate, and was not sensitive to other protease inhibitors that included benzamidine and trasylol.
The fact that antithrombin III plus heparin did not inhibit the activity of the IDL-and HDL-induced cellular prothrombinase does not exclude the possibility of a cell-associated Va-Xa prothrombinase complex comparable with that observed on the surface of activated platelets (27, 28 (30) . Second, the nature of the IDL-and HDL-inducible PCA was distinct from that described for either LPS (2) or other reported stimuli.
The present study demonstrates that plasma VLDL, IDL, and HDL classes can induce a dose-and timedependent expression of two types of PCA in cultured human PBM, whereas LDL cannot. In addition, small amounts of LDL can inhibit, in a dose-dependent manner, the amplification of cellular PCA induced by either VLDL, IDL, or HDL. Thus the reconstituted mixture of all four lipoprotein classes which represents an approximate relative physiological mixture has little if any capacity to induce cellular PCA in vitro. PBM circulate in plasma in the presence of all of these lipoproteins, and dose-dependent thresholds were observed for both the stimulation and the inhibition of PCA expression. Since these cells are not actively expressing maximal levels of PCA as recovered from the blood (Fig. 1) , and are subject to stimulation in vitro, it appears that one or more reversible physiological influences may maintain the system in a latent state in vivo. As a number of modes of initiating and dampening the coagulation system are known to occur in vivo, it is hypothesized that perturbations of plasma lipoprotein-regulated cellular PCA expression might play a role in certain hemostatic and thrombotic diseases.
The results of this study suggest that in physiological states associated with systemic or localized extravascular changes in the relative proportions ofdifferent plasma lipoproteins, critical lipoprotein concentrationdependent activation or inhibition of cellular PCA expression can occur. In this respect, no satisfactory mechanism has been brought forward to explain a variety of observed correlations between increased incidence of thrombogenesis and altered proportions of certain plasma lipoproteins. For example, a side effect of estrogen therapy, particularly associated with the use of oral contraceptives, is an increased incidence of venous thromboembolic disease and cerebral thrombosis (31) . An increase in morbidity and mortality from these conditions of about sixfold has been reported. In such individuals significant changes in plasma lipoproteins also have been observed. Estrogen therapy has been demonstrated to decrease plasma LDL and total cholesterol, and to increase plasma HDL cholesterol (32) . Whether these effects include increases of specific lipoproteins sufficient to stimulate PCA generation, and to decrease lipoproteins that inhibit PCA generation, merits study.
An increased incidence of thrombotic events is also observed in patients with certain hyperlipoproteinemias (33) . Lipoproteins isolated from certain hyperlipoproteinemic plasma appear to accelerate some clotting tests (9) ; and an increased incidence of accelerated intravascular coagulation occurs in the common type IV hyperlipoproteinemia, which is characterized by increased concentrations of VLDL (34) . This form of hyperlipoproteinemia has not been associated with elevated platelet sensitivity as occurs in type II hyperlipoproteinemia (34) . Whether VLDLinduced cellular PCA stimulation might be involved in the apparent nonplatelet-associated heightened intravascular coagulation will merit analysis. Finally, a satisfactory explanation of the pathogenesis of atherosclerosis continues to be elusive. Lipid deposition in vascular intimal smooth muscle cells in the presence of macrophages or foam cells, and local appearance of fibrin are prominent features of the atherosclerotic lesion (35, 36) . Whether perturbations of the lipoprotein-regulated network of monocyte activation to produce PCA may participate in the generation or progression of these lesions deserves consideration.
The implication of the present study that there is a biological relationship between plasma lipoproteins, lymphoid cells, and the coagulation system is not without precedent. In certain immunologically mediated tissue lesions such as the delayed cutaneous hypersensitivity reaction (37) , kidney allograft rejection (38) , experimental antiglomerular basement membranetype glomerulonephritis (39) , and experimental allergic encephalitis (40) , there is strong evidence that local activation of the coagulation system is a characteristic feature of the lesions in vivo. In these lesions, accumulations of mononuclear cells are prominent. In separate studies it has been observed that plasma lipoproteins can regulate lymphocyte function in vitro and in vivo (11) (12) (13) (14) . To our knowledge, however, the present study represents the first linkage of all three systems. The details of the cellular requirements and analysis of the role of plasma lipoproteins in the regulation of cellular PCA generation are considered in the accompanying study.
